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The mitogen-activated protein (MAP) kinase pathway is comprised of a three-tiered kinase 
cascade. The distributive kinetic mechanism of two-site MAP kinase phosphorylation inherently 
generates a non-linear switch-like response. However, a linear graded response of MAP kinase 
has also been observed in mammalian cells, and its molecular mechanism remains unclear. To 
dissect these input-output behaviors, we quantitatively measured the kinetic parameters involved 
in the MEK-ERK MAP kinase signaling module in HeLa cells. Using a numerical analysis based 
on experimentally determined parameters, we predicted in silico and validated in vivo that ERK 
is processively phosphorylated in HeLa cells. Finally, we identified molecular crowding as a 
critical factor that converts distributive phosphorylation into processive phosphorylation. We 
proposed the term quasi-processive phosphorylation to describe this mode of ERK 
phosphorylation that is operated under the physiological condition of molecular crowding. The 
generality of this phenomenon may provide a new paradigm for a diverse set of biochemical 





Mitogen-activated protein (MAP) kinase cascades are evolutionarily conserved signaling 
pathways that are involved in the control of physiological and pathological cellular processes 
including cell proliferation, survival, differentiation, apoptosis, and tumorigenesis (1-4). Each 
MAP kinase pathway contains a three-tiered kinase cascade consisting of a MAP kinase kinase 
kinase, a MAP kinase kinase, and the MAP kinase, which are sequentially activated in this order. 
MAP kinases, which are activated by dual phosphorylation of conserved threonine and tyrosine 
residues within the activation loop, phosphorylate their targets on serine or threonine residues (1, 
3, 5). Five distinct groups of MAP kinases have been characterized in mammals. Among them, 
the most studied is the Raf/MEK/ERK MAP kinase cascade (hereafter called the ERK MAP 
kinase cascade), which is activated by mitogenic ligands such as growth factors, cytokines, and 
phorbol esters. 
Ferrell and coworkers found that in Xenopus oocytes the ERK MAP kinase pathway responds 
to increasing levels of progesterone in an all-or-none or “switch-like” manner, in which 
individual cells in the population exhibit either “on” or “off” status (6, 7). This property of ERK 
MAP kinase system befits to determine all-or-none irreversible responses including cell-cycle 
progression, neuronal differentiation, and T cell selection (6-10). The switch-like responses can 
arise from both positive feedback via protein synthesis and dual phosphorylation steps of the 
MAP kinase, which is called the “distributive phosphorylation model” (11-15) (Fig. 1A). The 
distributive model of ERK phosphorylation results in an increase in the cooperativity of this 
system, and consequently contributes to a switch-like input-output response.  
 4 
In different cellular contexts, however, the ERK MAP kinase cascade exhibits “graded” 
response, in which all cells in the population uniformly gain their signal output proportionally in 
response to the level of input stimulus. This input-output response is observed in the 
pheromone-stimulated S. cerevisiae (16-18) and growth factor stimulated-HeLa cells and 
fibroblasts (19, 20). These graded responses can suit the physiological property of signaling, 
including the reversibility and the activation by different inputs with a wide range of threshold 
doses (18). However, MAP kinase cascades should inherently induce the switch-like response 
behavior due to the three-tiered enzyme cascade. To answer this question, it has been 
theoretically proposed that scaffold proteins might convert the switch-like response into the 
graded response (21). Here, the scaffold protein holds MAP kinase kinase and MAP kinase, 
thereby inducing dual phosphorylation at a single collision, which is called the “processive 
phosphorylation model” (11, 21-25). However, it is not known whether the scaffold proteins in 
mammals contribute to the processive phosphorylation of MAP kinase (10). Hence, the 
mechanism by which MAP kinase activity adopts a graded response remains unclear in 
mammalian cells.  
In this study, we demonstrate for the first time that ERK is phosphorylated in a processive 
manner by employing quantitative simulation model of the ERK MAP kinase cascade. 
Furthermore, a condition that mimics physiological molecular crowding has been shown to 
convert the mode of ERK phosphorylation from distributive to processive. Under this condition, 
MEK and ERK do not form a stable complex as proposed in the processive phosphorylation 
model. Therefore, we propose that ERK is phosphorylated in a “quasi-processive” manner under 




Kinetic parameters that determine the dynamics of the MEK-ERK signaling module 
Our goal is to comprehend the systems behavior of the MEK-ERK signaling module. To this end, 
we attempted to determine most, if not all, of the kinetic parameters required for the kinetic 
simulation model, using HeLa cells as a model system. The model requires four classes of 
parameters: protein concentrations, association/dissociation rates, nuclear import/export rates, 
and phosphorylation/dephosphorylation rates. We experimentally determined approximately 30 
parameters (SI Appendix, Fig. S1-7 and Tables S1 and S2). Notably, this study focused on the 
phosphorylation kinetics of the MEK-ERK module in the early phase of the signaling event. 
Thus, we neglected the role of ERK-induced gene expression of negative regulators such as dual 
specificity phosphatases (DUSPs), which shape the dynamics of intracellular signaling starting 
from 30 min after ligand addition (26). 
 
In vitro phosphorylation rates of ERK measured by Phos-tag gel electrophoresis 
All parameters used in this study are determined in living HeLa cells except for the 
phosphorylation rates of ERK, which was determined as follows. MEK activates ERK by 
phosphorylating two critical amino acid residues within the activation loop, threonine and 
tyrosine; therefore, we quantified four phospho-isoforms of ERK, non-phosphorylated ERK 
(np-ERK), tyrosine mono-phosphorylated ERK (pY-ERK), threonine mono-phosphorylated ERK 
(pT-ERK), and bis-phosphorylated ERK (pTpY-ERK) by Phos-tag western blotting (27). 
Phos-tag is a phosphorylated amino acid chelator. Because the electrophoretic mobility of 
phosphorylated proteins is significantly reduced in separation gels containing Phos-tag, the 
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fractions of non-phosphorylated and phosphorylated proteins can be visualized quantitatively. 
Notably, the effect of Phos-tag on the electrophoretic mobility varies among phospho-proteins, 
demanding a preliminary experiment of the identification of each phospho-protein by 
immunoblotting with specific antibodies (SI Appendix, Fig. S4). We found that the order of 
electrophoretic mobility in the Phos-tag gel was, from the slowest to fastest, pY-ERK, 
pTpY-ERK, pT-ERK, and np-ERK. This order was also confirmed with phosphatase inhibitors. 
Treatment with the phospho-tyrosine phosphatase inhibitor bpV, and the 
phospho-serine/threonine phosphatase inhibitor Calyculin A, increased the intensity of the 
pY-ERK and pT-ERK bands, respectively (SI Appendix, Fig. S6). 
The rates of ERK phosphorylation by MEK were first determined in vitro using a kinase-dead 
mutant of ERK2 (ERK2-KR) and constitutively active mutant of MEK1 (MEK1-SDSE). As 
previously demonstrated (11), pY-ERK was initially accumulated, followed by pTpY-ERK (Fig. 
1B and 1C). pT-ERK could not be detected under this condition. Importantly, the amount of the 
intermediate product, pY-ERK, exceeded that of the enzyme, MEK1-SDSE (3.0 x 10
-7
 M in Fig. 
1C), indicating that ERK was phosphorylated by a manner consistent with the distributive 
phosphorylation model in vitro (11). In this way, we obtained the first and second reaction rates 
with linear assumption (kcat/Km) of 3.9 x 10
4
 [/M/sec] and 2.1 x 10
4
 [/M/sec], respectively (SI 
Appendix, Fig. S5 and Table S2). The reason why pT-ERK was not detected may be because the 
first step of the reactions from np-ERK to pT-ERK is markedly slower than the second step from 
pT-ERK to pTpY-ERK in vitro. Therefore, the phosphorylation reaction rate (kcat/Km) from 
pT-ERK to pTpY-ERK was examined in vitro using pT-ERK as a substrate, and was found to be 
2.0 x 10
4
 [/M/sec] (SI Appendix, Table S2). Thus, pT-ERK production from np-ERK could be 
ignored at least in the phosphorylation reactions (SI Appendix, Fig. S5G).  
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Validation of the distributive phosphorylation model 
Based on these parameters determined experimentally (SI Appendix, Tables S1 and S2), we built 
a distributive phosphorylation model of the MEK-ERK signaling module (Fig. 2A and SI 
Appendix, Fig. S8A), and numerically solved the ERK phosphorylation (Fig. 2B and 2C). The 
input signal, i.e., the turnover rate of MEK phosphorylation by cRaf, was initially set to 1.0 x 10
6
 
[/M/sec] to reproduce the experimental data, and was varied with a broad range (SI Appendix, 
Fig. S9). Upon stimulation in silico, pY-ERK was steeply increased, followed by a gradual 
increase in pTpY-ERK and pT-ERK (Fig. 2B). pY-ERK was predominant over pTpY-ERK in low 
input strength, and vice versa for high input strength at 10 min after stimulation (Fig. 2C). These 
data were consistent with the distributive phosphorylation model demonstrated in vitro (Fig. 1) 
and in Xenopus oocytes (6, 11).  
We next examined whether the phosphorylation of ERK2 in HeLa cells follows the 
distributive model. Against the prediction in silico, the increase in pY-ERK2 did not precede to, 
but rather accompanied the increase in pTpY-ERK2 upon EGF stimulation (Fig. 2D and 2E). 
Furthermore, pY-ERK2 increased in a dose-dependent manner as the EGF input increased (Fig. 
2F and 2G), but did not increase in a bell-shaped manner as predicted in silico (Fig. 2C). Of note, 
we could not detect the endogenous pT-ERK2 quantitatively due to the low abundance and to the 
signals of co-migrating pY-ERK1.  
 
Prediction of a processive phosphorylation model in silico 
Because we determined all parameters in the cells except for the phosphorylation reaction rates, 
which were obtained in vitro, we speculated that the discrepancy between the experimental and 
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in silico data of the MEK-induced ERK phosphorylation might have arisen from parameters 
related to the phosphorylation rates of ERK. Hence, we built a processive model by changing 
one reaction pathway of the distributive model (Fig. 3A and SI Appendix, Fig. S8B, Tables S1 
and S2). Here, activated MEK does not dissociate from pY-ERK but processively phosphorylates 
threonine of pY-ERK to generate pTpY-ERK. Therefore, this model contains two species of 
pY-ERK, i.e. pY-ERK in complex with MEK and pY-ERK generated by the dephosphorylation 
of pTpY-ERK. 
With this processive model, the experimental observation (Fig. 2D-2G) was reproduced 
successfully (Fig. 3B, 3C and SI Appendix, Fig. S9). Namely, the increase in pY-ERK paralleled 
the increase in pTpY-ERK both in the time course analysis and the input-output response 
analysis. These results implied that ERK is processively phosphorylated by MEK.  
 
Experimental validation of the processive model 1: pY-ERK dynamics 
By employing computer-assisted kinetic simulation, we designed an experimental condition that 
distinguishes between the distributive model and the processive model. When cells are 
stimulated in the presence of phosphatase inhibitors, pY-ERK will be increased in the distributive 
model (Fig. 4A, green lines, and SI Appendix, Fig. S10A) and decreased in the processive model 
(Fig. 4B, green lines, and SI Appendix, Fig. S10B). This is because pY-ERK is generated 
primarily as the intermediate phosphorylation product in the distributive model, whereas in the 
processive model pY-ERK is produced by the dephosphorylation of pTpY-ERK. For the 
execution of the designed experiment, HeLa cells were stimulated with EGF in the absence or 
presence of inhibitors for tyrosine- and serine/threonine-phosphatase, bpV and Calyculin A, 
respectively. As expected in the processive model, phosphatase inhibitors substantially reduced 
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the accumulation of pY-ERK, arguing for the processive phosphorylation model (Fig. 4C and 
4D).  
 
Experimental validation of the processive model 2: Input-output response 
Previous studies supported the distributive phosphorylation model primarily because it explains 
the non-linear switch-like response of MAP kinase upon stimulation. Therefore, to understand 
the contribution of the MEK-ERK signaling module to the switch-like response of ERK to EGF, 
we examined the input-output behavior of ERK phosphorylation in our experimental conditions. 
We quantified the amount of pTpY-ERK1/2 in individual cells by immuno-staining with 
anti-pTpY-ERK1/2 antibody. As reported previously in HeLa cells and fibroblasts stimulated 
with EGF and TPA, respectively (19, 20), this approach could provide quantitative relationship 
between the input signal and output response (Fig. 5A and 5B). The Hill coefficient obtained by 
this method was 2.09 (Fig. 5B). Next, we confirmed this observation by western blotting, which 
also demonstrated a mild non-linear cooperativity, having 1.91 Hill coefficient (Fig. 5C). 
However, when we examined the correlation of the fraction of active MEK with the fraction of 
pTpY-ERK, we observed almost linear input-output response of ERK, having 1.18 Hill 
coefficient (Fig. 5D). Importantly, this Hill coefficient value determined experimentally was 
nearly identical to the Hill coefficient calculated at 1.19 by the processive model (Fig. 5F), but 
significantly smaller than the Hill coefficient calculated at 1.61 by the distributive model (Fig. 
5E). Notably, the Hill coefficients might be slightly overestimated because they were calculated 
at the time point before reaching plateau. Nevertheless, these results strongly supported the 
processive model, which should exhibit linear input-output response.  
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Numerical validation of the processive model 
To examine which of the distributive and processive models is the plausible mechanism to 
account for the observed data (Fig. 2E and Fig. 4D), we calculated residual sum of squares (RSS) 
values, Akaike information criterion (AIC) values, and Hill coefficients for both models after 
parameter fitting (28) (Fig. S11). This in silico validation was performed under three conditions 
of different numbers of variables. Condition 1: all phosphorylation rates were multiplied by a 
common constant value, which was optimized to fit the experimental data. Condition 2: the 
phosphorylation rates were individually fitted to the experimental data. Condition 3: in addition 
to the phosphorylation rates, the dephosphorylation rates were also fitted individually to the 
experimental data. In all conditions, experimentally-determined parameters were used as the 
initial values for the fitting. In Conditions 1 and 2, the processive model was more plausible than 
the distributive model because the AIC of the former model was smaller than the AIC of the 
latter model. Although both distributive and processive models exhibited the lowest RSS in 
Condition 3, the AIC values were higher than those in the other conditions, which indicated 
over-fitting in Condition 3. Importantly, the Hill coefficients calculated by the processive model 
were closer to the experimental value than the Hill coefficients calculated by the distributive 
model (Fig. 5F). Taken together, these analyses strongly argued that ERK is processively 
phosphorylated by MEK in HeLa cells.  
 
Molecular crowding as a determinant for processive phosphorylation 
What kind of factor(s) is a critical determinant for changing the distributive nature of ERK 
phosphorylation into the processive one in the cells? A critical difference between the 
environment in vitro and that within cells is the effect of molecular crowding (29, 30). To 
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evaluate the effect of molecular crowding, we examined whether or not ERK is phosphorylated 
in a processive manner in diluted cytoplasmic cell extract. Similarly to the results of in vitro 
ERK phosphorylation, ERK is phosphorylated in a distributive manner in the cytoplasmic extract, 
which was manifested by the initial accumulation of pY-ERK (SI Appendix, Fig. S12). 
Conversely, we mimicked the physiological molecular crowding by adding 15% (wt/vol) 
polyethylene glycol (PEG) to in vitro kinase reaction solution as a crowder (31) (Fig. 6A and 6B). 
The addition of PEG reduced the production rate of pY-ERK without changing the net 
production rate of pTpY-ERK, indicating an increase in the “processivity” of ERK 
phosphorylation (Fig. 6C and 6D). Lastly, we built a partial processive model by combining the 
distributive and processive models and fitted it to the experimental data (Fig. 6E). For this we 
introduced two additional parameters: Processivity, p, as the probability of pTpY-ERK 
production in the processive manner, and crowding factor, c, as the effect of the crowder or 
viscosity on the net reaction rates. By the fitting we found that the presence of 15% PEG 
increased in the processivity of ERK phosphorylation of 47%, and decreased the reaction rates to 
27% by viscosity (Fig. 6C and 6D). Of note, the amount of pY-ERK at the zenith exceeded the 
net amount of MEK (Fig. 6D, dashed line), indicating that pY-ERK was not accumulated due to 
the sequestration by MEK binding. Thus, the molecular crowding within the cells could convert 
the distributive phosphorylation in vitro to the processive phosphorylation as seen in the cells.
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Discussion 
In this study, we have demonstrated for the first time that the amino acid residues in the 
activation loop of ERK, threonine and tyrosine, are processively phosphorylated in HeLa cells, 
and have identified molecular crowding as one possible factor in determining whether the mode 
of phosphorylation will be distributive or processive. The term “processive phosphorylation” is 
used to describe reactions in which the substrate-enzyme complex is stable during the first and 
second phosphorylation reactions, which is not the case for the phosphorylation of ERK (Fig. 
6D). We therefore proposed the term “quasi-processive phosphorylation” to describe two 
sequential phosphorylation reactions that are controlled by molecular crowding (Fig. 6F). In this 
model, MEK first phosphorylates ERK at the tyrosine residue and dissociates from the product, 
pY-ERK. Under the physiological conditions within cells, the diffusions of both MEK and 
pY-ERK are considerably restricted by the molecular crowding effect; therefore, MEK rebinds to 
and phosphorylates pY-ERK with high probability. Consequently, MEK phosphorylates ERK in a 
processive manner. Another MAP kinase, p38, also exhibited typical hallmarks of the processive 
phosphorylation (SI Appendix, Fig. S13), indicating the generality of the quasi-processive 
phosphorylation of MAP kinase within cells. In contrast to the phosphorylation step, this 
quasi-processive phosphorylation model could not be applicable to the dephosphorylation step of 
pTpY-ERK, because the premise of quasi-processive phosphorylation is sequential reactions 
operated by the identical enzyme. The dephosphorylation reactions of phospho-threonine and 
phospho-tyrosine were mediated probably by different classes of phosphatase at least in our 
experimental conditions (SI Appendix, Fig. S6).  
The quasi-processive phosphorylation is critically different from the previously proposed 
processive phosphorylation model, in which scaffold proteins anchor MEK and ERK in order to 
cause sequential phosphorylation reactions by a single collision (21). The scaffold proteins are 
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known to regulate assembly of two or more components of signaling pathways in many signaling 
cascades (21-25). As far as we have examined, however, none of the scaffold proteins for MEK 
and ERK contributed significantly to cause the processivity of ERK phosphorylation (SI 
Appendix, Fig. S14), consistent with the previous study on KSR (10).Therefore, at this moment, 
we failed to obtain any evidence that scaffold proteins cause processive phosphorylation in 
mammalian cells. Importantly, Takahashi and Pryciak have concluded that sole expression of 
Ste5 scaffold did not induce linear response of MAP kinase phosphorylation in yeast, and instead 
the recruitment of the scaffold to the plasma membrane resulted in linear response of MAP 
kinase phosphorylation (18). This seems to fit very well with our findings, in that the effect of 
Ste5 could be due to molecular crowding or confinement, rather than scaffolding per se. Recently, 
Takahashi et al, demonstrated by particle simulation that rapid rebinding of enzyme molecules to 
the substrate after modification of the first site can turn a distributive model into a processive 
model (32). They have predicted that molecular crowding will make enzyme-substrate 
rebindings more likely due to subdiffusion, strongly providing the theoretical basis of our 
findings. 
It has been suggested that the high cooperativity of Xenopus oocytes in reaction to 
progesterone stimulation is at least partly accomplished by the distributive phosphorylation of 
ERK (6, 7). Some degree of molecular crowding probably exists in Xenopus oocytes, indicating 
an important point of disagreement between these previous studies and our present findings. 
However, it should be noted that the phosphorylation dynamics of ERK phospho-isoforms has 
only been investigated in vitro, and has never been investigated experimentally in Xenopus 
oocytes or cells. Therefore, it is possible that ERK is processively phosphorylated in Xenopus 
oocytes as in HeLa cells. There may exist non-linear reactions in the signaling pathway upstream 
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of MEK, e.g., receptor phosphorylation or Mos activation, in Xenopus oocytes. Actually, the 
input-output relationship between EGF concentration and pTpY-ERK demonstrated higher 
cooperativity; namely, the Hill coefficient was almost two (Fig. 5A-C). In contrast, the Hill 
coefficient for active MEK and pTpY-ERK phosphorylation was approximately one, implying 
the presence of a non-linear reaction(s) in the signaling cascade upstream of MEK. Consistent 
with this assumption, it has been reported that EGFR phosphorylation responded in a highly 
amplified and switch-like manner by coupling EGFR activation and PTP inhibition (33).  
As has been described in this study, the discrepancy between the data acquired from the cells 
and the data predicted by the kinetic simulation model led us to the finding that ERK is 
processively phosphorylated within cells. Therefore, our results underscore the importance of 
simulation models based on experimentally determined kinetic parameters. Another important 
message from this study is that, in some cases, the physiological condition of molecular 
crowding significantly affected the mode of phosphorylation. Recent proteomic data 
demonstrates that proteins in a eukaryotic cell harbor multiple phosphorylation sites, each of 
which regulates different functions of their proteins (24). Therefore, molecular crowding, which 
is ubiquitous in biological systems, introduces additional complexity in their regulation. Thus, 
the finding that molecular crowding changes the mode of successive reactions to a processive 
type provides a new paradigm for a diverse set of biochemical reactions.  
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Materials and Methods 
 
Plasmids, cells, reagents and antibodies 
The plasmids used here were constructed according to the standard methods. Cells, reagents and 
antibodies are detailed in SI Appendix.  
Purification of recombinant proteins, cytoplasm extract and in vitro kinase assay 
Details of purification of recombinant proteins, cytoplasmic extract and in vitro kinase assay are 
provided in SI Appendix.  
Phos-tag polyacrylamide gel electrophoresis 
Phos-tag polyacrylamide gel electrophoresis was performed essentially as described previously 
(27). For Phos-tag western blottings of ERK and p38, 5.0 x 10
-5
 and 1.5 x 10
-4
 M Phos-tag and 
1.0 x 10
-4
 and 3.0 x 10
-4
 M MnCl2 were added to conventional SDS-polyacrylamide separation 
gels according to the manufacturer’s protocol, respectively. Proteins were detected by using an 
Odyssey Infrared Imaging System (LI-COR). 
Imaging 
Live cell imaging was performed essentially as described (34). 
Kinetic modeling and numerical simulation 
Numerical simulation and parameter search were implemented by MATLAB software with 
ode23 and fminsearch function, respectively. The details are described in SI Appendix. 
Immunostaining 
Details of pTpY-ERK immunostaining are provided in SI Appendix. 
Data analysis 
For the determination of kinetic parameters, curve fitting were performed by the solver function 
 16 
of Microsoft excel (Microsoft, WA). 
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Fig. 1. ERK phosphorylation in vitro. (A) Schematic representation of the input-output 
response of ERK MAP kinase. The distributive phosphorylation model leads to switch-like 
response. On the other hand, no model is currently validated for the graded response of ERK, 
which is observed in mammalian cells and yeast. (B) His-tagged MEK1-SDSE and 
GST-ERK2-KR were incubated with ATP for the indicated periods, followed by Phos-tag 
western blotting analysis. All phospho-isoforms of ERK were detected by anti-GST rabbit 
antibody (upper) and IRDye680-conjugated anti-rabbit IgG antibody as a secondary antibody. 
The positions of the phospho-isoforms of ERK are indicated at right (SI Appendix, Fig. S4). 
pTpY-ERK was simultaneously detected by anti-pTpY-ERK mouse antibody (middle) and 
IRDye800-conjugated anti-mouse IgG antibody as a secondary antibody. The lower image is the 
merged image (Red: ERK, Green: pTpY-ERK). (C) The phospho-isoforms of ERK were 
quantified and plotted with SD (n = 3).  
 
Fig. 2. Numerical and experimental analyses of the distributive phosphorylation model. (A) 
Schematic representation of the distributive model (see SI Appendix, Fig. S8A in detail). (B and 
C) Results of numerical simulations are represented based on experimentally determined 
parameters (SI Appendix, Tables S1 and S2). (B) Concentrations of np-ERK (blue), pY-ERK 
(green), pTpY-ERK (red) and pT-ERK (orange) are plotted against time. The kcat/Km value of 
cRaf kinase for MEK phosphorylation (Raf_kphos) is 1.0 x 10
6
 [/M/sec]. (C) Concentrations of 
the phospho-isoforms of ERK are plotted against the Raf_kphos value at time = 10 [minutes]. (D 
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and E) After serum starvation, HeLa cells were stimulated with 1.0 x 10
-5
 g/l EGF at the 
indicated time period. (D) Cell lysates were separated by SDS-polyacrylamide gel containing 
Phos-tag and probed with an anti-ERK antibody. (E) The amounts of np-ERK2 (blue), pY-ERK2 
(green), and pTpY-ERK2 (red) are plotted against time after EGF stimulation with SD (n = 3). (F 
and G) After serum starvation, HeLa cells were stimulated with the indicated concentration of 
EGF for 7.5 min. (F) Cell lysates were analyzed by Phos-tag western blot analysis as in D. (G) 
The amounts of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) are plotted as a 
function of the EGF concentration with SD (n = 5). 
 
Fig. 3. Computational simulation of the processive phosphorylation model. (A) Schematic 
representation of the processive model (see SI Appendix, Fig. S8B in detail). (B) Results of 
numerical simulations are represented based on experimentally determined parameters (SI 
Appendix, Tables S1 and S2). Time series of np-ERK (blue), pY-ERK (green), pTpY-ERK (red) 
and pT-ERK (orange) concentrations are plotted at Raf_kphos value = 1.0 x 10
6
 [/M/sec]. (C) 
Concentrations of the phospho-isoforms of ERK are plotted as a function of Raf_kphos value at 
time = 10 (min).   
 
Fig. 4. Validation of the processive model by pY-ERK dynamics. (A and B) Numerical 
simulations were performed based on the distributive model (A) and the processive model (B) in 
the absence (left column) or presence of the inhibition of all phosphatase reactions (right 
column). Time series of np-ERK (blue), pY-ERK (green), pTpY-ERK (red) and pT-ERK (orange) 
concentrations are plotted at Raf_kphos value = 1.0 x 10
6
 [/M/sec]. Maximal levels of pY-ERK 
without inhibition are indicated by gray dashed lines. (C and D) After serum starvation, HeLa 
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cells were treated with mock or 1.0 x 10
-7
 M Calyculin A and 1.0 x 10
-4
 M bpV for 2 min, 
followed by 1.0 x 10
-5
 g/l EGF for the indicated time period. (C) Cell lysates were separated by 
electrophoresis in SDS-polyacrylamide gels containing Phos-tag and probed with an anti-ERK 
antibody. (D) Time series of np-ERK2 (blue), pY-ERK2 (green), and pTpY-ERK2 (red) 
concentrations without (left) or with (right) phosphatase inhibitors are plotted after EGF 
stimulation with SD (n = 4). 
 
Fig. 5. Validation of the processive model by input-output response. (A and B) Serum-starved 
HeLa cells were stimulated with the different concentration of EGF (blue, 0.01; cyan, 0.03; green, 
0.1; yellow, 0.3; orange, 1.0; pink, 3.0; red, 10 (x 10
-6
 [g/l])) or 2.0 x 10
-5
 M U0126 (black) for 5 
min, and then stained with anti-pTpY-ERK1/2 antibody. (A) Fluorescent signals in each cell are 
represented in a histogram, demonstrating unimodal distributions (n > 90 cells). (B) The average 
fluorescent intensities are plotted as a function of EGF concentration with SD. Hill coefficient 
value, nH, was obtained by curve fitting with standard Hill equation (black line). (C) The 
average of fraction of pTpY-ERK are plotted as a function of EGF concentration with SD (n = 5). 
This data is same as shown in Fig. 2G (red line). (D) The average of fraction of pTpY-ERK was 
plotted as a function of ratio value of phosphorylated MEK1/2 to total MEK1/2 with SD (n = 5). 
(E and F) The pTpY-ERK concentration at time = 10 (min) after stimulation in distributive (E) 
and processive (F) model are plotted as a function of phosphorylated MEK concentration.  
 
Fig. 6. Effect of molecular crowding on processive phosphorylation. (A and B) ERK was 
phosphorylated by MEK in the absence (A) or presence (B) of 15% (w/v) polyethylene glycol 
(PEG) in vitro and were subjected to Phos-tag western blotting analysis. (C and D) The 
 25 
concentrations of phospho-isoforms of ERK in A and B are plotted as dots against time. 
Concentration of constitutively active mutant of MEK (1.0 x 10
-7
 M) used in these experiments is 
indicated by gray dashed lines. The same experiments were repeated four times with 
reproducible results, and representative results are shown. Lines represent the concentration of 
phospho-isoforms of ERK obtained by fitting the processive model in panel E with the 
experimental data. The fitted parameters of processivity (p) and crowding factor (c) are 
represented. (E) Schematic representation of processive phosphorylation. p and c indicate 
processivity (0<p<1) and crowding factor, respectively. (F) Schematic view of quasi-processive 
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Supporting Information Appendix: 
Processive phosphorylation of ERK MAP kinase in mammalian cells. 




Dephosphorylation rates of ERK in the cytoplasm and 
nucleus. We determined eight dephosphorylation rates of 
ERK; i.e., pTpY-ERKpY-ERK, pTpY-ERKpT-ERK, 
pY-ERKnp-ERK, and pT-ERKnp-ERK in each of two 
compartments, i.e., the cytoplasm and nucleus (Fig. S6). 
Because several phosphatases, including PTP1B, PP2A, and 
DUSPs, have reported to be involved in ERK dephosphorylation 
(1), we attempted to measure the rate constant [/sec] of each 
dephosphorylation pathway for the cytoplasm and nucleus as the 
mass of phosphatases. To this end, we established HeLa cell 
lines stably expressing ERKs tagged with a nuclear export 
sequences (NES) or a nuclear localization signals (NLS). The 
cells were treated with EGF followed by an MEK inhibitor, 
PD184352, to measure the dephosphorylation rates (Fig. S6A, 
left column). Calyculin A, a serine/threonine phosphatase 
PP1/PP2A inhibitor, or bpV, a tyrosine phosphatase inhibitor, 
was also used to discriminate the two dephosphorylation 
reactions (Fig. S6A, center and right columns). Finally, the time 
constants for each dephosphorylation pathway were determined 
by curve-fitting the concentration of phospho-isoforms of ERK 
with a single exponential decay function (Fig. S6B-K). Notably, 
we observed accumulation of pT-ERK and pY-ERK in the 
presence of Calyculin A and bpV, respectively (Fig. S6A). This 
observation indicated that the dephosphorylation of pTpY-ERK 
was primarily mediated by serine/threonine phosphatases and 
tyrosine phosphatases, rather than dual-specificity phosphatases, 
at least in our experimental conditions. Furthermore, the 
dephosphorylation rate of MEK was also determined and 
included in our simulation model (Fig. S7). Of note, we 
neglected the effect of phosphatase inhibitors on Raf and MEK, 
because they will not affect the mode of ERK phosphorylation.  
 
Involvement of Scaffold proteins in the processive 
model. Feasible candidates for the determinant of the 
processive phosphorylation include scaffold proteins, which 
regulate assembly of two or more components of signaling 
pathways and consequently change the mode of phosphorylation 
(2-6). To examine the contribution of scaffold proteins to the 
processive phosphorylation, we depleted KSR, MP-1, IQGAP1, 
Paxillin, or -arrestin1/2 in HeLa cells by siRNA-mediated gene 
knockdown (7-11). The depletion of each scaffold protein could 
affect the phosphorylation efficiency of ERK in HeLa cells 
stimulated with EGF, but not alter the mode of ERK 
phosphorylation, namely processive phosphorylation, to the 
detectable level (Fig. S14). For this reason, at this moment, we 
failed to obtain any evidence that scaffold proteins cause 




SI Materials and Methods 
 
Plasmids. The cDNA of Xenopus MEK1 or Xenopus ERK2 
was inserted into pCXN2-mVenus or pCXN2-mCFP vector to 
generate pCXN2-mVenus-MEK1, pCXN2-mCFP-MEK1, or 
pCXN2-mCFP-ERK2 (Fig. S2). Monomeric Venus (mVenus) or 
CFP (mCFP) was fused at the N-terminus of these vectors. The 
cDNA of FKBP (12) was introduced into these vectors to obtain 
pCXN2-mVenus-MEK1-FKBP and 
pCXN2-mVenus-ERK2-FKBP (Fig. S3). Threonine or tyrosine 
within the activation loop of ERK2 was replaced with alanine 
and phenylalanine, respectively, to obtain 
pCXN2-mVenus-ERK2T188A-FKBP and 
pCXN2-mVenus-ERK2Y190F-FKBP, respectively (Fig. S3). 
pCAGGS-FLAG-FRB-NES was designed to express FLAG tag, 
the FKBP-rapamycin-binding (FRB) domain of the mammalian 
target of rapamycin, and the nuclear export sequence (NES) of 
HIV rev protein (LQLPPLERLTLD) from the N-terminus. The 
cDNAs of human Histon H1 (the kind gift of Dr. Ishikawa) and 
FRB were prepared by PCR and subcloned into pERedNLS 
vector (pERedNLS-H1-FRB) (13) (Fig. S3). The cDNA of 
mouse ERK2 or human MEK1 was subcloned into the modified 




pCX4bsr-NES-FLAG-ERK2-mVenus encoded NES, FLAG tag, 
ERK2, and mVenus from the N-terminus (Fig. S6). 
pCX4bsr-FLAG-ERK2-mCFP-NLS was designed to express 
FLAG tag, ERK2, mCFP and the nuclear localization signal 
(NLS) of SV40 large T antigen (GGPPKKKPKVEDP). 
pCX4puro-NLS-FLAG-MEK1 encoded NLS, FALG tag and 
MEK1 from the N-terminus. A fragment of the kinase-deficient 
mutant of Xenopus ERK2 (ERK2-KR) was inserted into the 
pGEX4T3 vector to obtain pGEX4T3-ERK2-KR (Figs. 1, 6, S2, 
and S5). The cDNA of the wild type Xenopus MEK1 
(MEK1WT), constitutively active mutant MEK1 (MEK1SDSE), 
or human PTP1B (the kind gift of Dr. B. Neel) was subcloned 
into the pET-12HisFLAG vector, which was designed to express 
double histidine hexamer-tagged FLAG peptide at the 
N-terminus (Figs, 1, 6, S2, S4, S5, and S12). 
 
Cells, reagents and antibodies. HeLa cells were purchased 
from the Human Science Research Resources Bank (Sennan-shi, 
Japan). HeLa cells were maintained in DMEM (Sigma-Aldrich, 
St. Louis, MO) supplemented with 10% fetal bovine serum 
(FBS). HEK-293F cells were purchased from Invitrogen (San 
Diego, CA), and maintained in FreeStyle 293 Expression 
Medium (Invitrogen). Expression plasmids were transfected into 
HeLa cells by 293Fectin (Invitrogen) according to the 
manufacturer’s instructions. EGF was purchased from 
Sigma-Aldrich. Calyculin A, bpV(phen), ZM336372, and 
anisomycin were purchased from Calbiochem (La Jolla, CA). 
PD184352 was obtained from Toronto Research Chemicals 
(Ontario, Canada). Phos-tag acrylamide was obtained from the 
Phos-tag Consortium (http://www.phos-tag.com/). Fluorescent 
beads for calibration of Venus and CFP were purchased from 
Invitrogen (InSpeck Green (505/515) Microscope Image 
Intensity Calibration Kit) and from Polyscience (Fluoresbrite 
Plain YG 0.1 micron Microspheres) (Warrington, PA). 
Anti-MEK1/2, anti-ERK1/2, anti-p38, anti-phospho-MEK1/2 
(Ser217/221), anti-phospho-ERK1/2 (Thr202/Tyr204 and 
Thr185/Tyr187, respectively), and anti-phsopho-p38 
(Thr180/Tyr182) were purchased from Cell Signaling 
Technology (Beverly, MA). Anti-cRaf monoclonal antibodies 
came from BD Transduction Laboratories (San Jose, CA). 
Anti-pY-ERK and anti-pT-ERK monoclonal antibodies were 
purchased from Sigma. Anti-GFP and anti-GST rabbit sera 
were prepared in our laboratory (15, 16). LI-COR blocking 
buffer, IRDye680- and IRDye800-conjugated anti-rabbit and 
anti-mouse IgG secondary antibodies were obtained from 
LI-COR Bioscience (Lincoln, NE). Polyethylene glycol 6000 
was purchased from Hampton Research (Aliso Viejo, CA). 
 
Establishment of stable cell lines. For generation of HeLa 
cell lines stably expressing ectopic proteins, we utilized a 
retroviral system. The murine ecotropic retrovirus receptor 
(EcoVR) was first introduced into HeLa cells by retroviruses 
produced from BOSC23 cells, which had been transfected with 
pCX4hyg-EcoVR, the packaging plasmid pGP, and the envelope 
plasmid pVSV-G (14). The HeLa cells stably expressing EcoVR 
were selected by Hygromycin. Then, HeLa-EcoVR cells were 
infected with retroviruses obtained from 
pCX4bsr-NES-FLAG-ERK2-mVenus-, 
pCX4bsr-FLAG-ERK2-mCFP-NLS-, or 
CX4puro-NLS-FLAG-MEK1-transfected BOSC23 cells (Fig. 
S6).  
 
Purification of recombinant proteins and in vitro 
kinase assay. Recombinant proteins fused to GST-tag and 
His-tag were expressed in E. coli strain BL21-DE3 from pGEX- 
and pET-derived vectors and purified as described previously 
(16). GST-tagged human MEK1, GST-tagged human ERK2, and 
GST-tagged human cRaf deleted with the N-terminus (kinase 
active mutant) were purchased from Millipore (Bedford, MA). 
For preparation of GST-pT-ERK2, plasmids of both 
pGEX-ERK2-KR and pET-12HisFLAG-MEK1SDSE were 
cotransformed into E-coli strain BL21-DE3. Fully 
phosphorylated-GST-ERK2 (pTpY-ERK2) was purified and 
incubated with recombinant 12HisFLAG-PTP1B to 
dephosphorylate phospho-tyrosine in dephosphorylation buffer 
(100 mM Tris [pH 7.5], 100 mM NaCl, 1 mM EDTA, 2 mM 
DTT). The GST-pT-ERK2 was then further purified. For in vitro 
kinase assay, GST-ERK2 or GST-pT-ERK2 with 
12HisFLAG-MEK1SDSE was incubated in in vitro kinase 
buffer (50 mM Tris [pH 7.5], 10 mM MgCl2, 0.02% BSA 0.2 
mM DTT). The reaction was started by adding 5 x ATP solution 
(5 mM ATP, 50 mM MgCl2, 25 mM Tris [pH 7.2], 0.15 M 
NaCl) and stopped at the indicated time point by adding SDS 
sample buffer. 
 
Preparation of cytoplasmic extract. For preparation of 
cytoplasmic extract, HEK-293F cells were collected by 
centrifugation. The packed cells were snap-frozen, followed by 
rapid thawing in water bath. After centrifugation, the 
supernatant was collected and used as cytoplasmic extract. The 
extract was diluted 10-fold for in vitro kinase reaction. 
 
Immunostaining. Cells were fixed with 3.7% formaldehyde 
and permeabilized with 0.2% Triton X-100. After having been 
soaked for 1 h in phosphate-buffered saline (PBS) containing 
3% BSA and 0.02% Triton X-100, the samples were incubated 
for 1 h at room temperature with 5 g/ml anti-pTpY-ERK 
antibodies, washed with PBS, and then incubated for 30 min at 
room temperature with Alexa 488 anti-mouse IgG,. The samples 
were washed with PBS containing 0.2% Tween 20, and imaged 
with an Olympus FV1000 microscope.  
 
Measurement of the dissociation constant by 
intermolecular FRET assay. First, images of YFP, CFP and 
FRET were acquired, and then corrected FRET (cFRET) images 
were created by subtracting the contributions of cross-excitation 
and bleed-through as follows: 
])[55.0(])[089.0(][][ CFPYFPFRETcFRET 
, 
where 0.089 and 0.55 indicate the degree of cross-excitation and 
spectral bleed-through under our microscopic conditions, 
respectively (17). cFRET and the cFRET/YFP ratio indicate the 
amount of bound protein and the fraction of acceptor protein 
that contribute to FRET, respectively. Concentrations of 
fluorescent proteins were evaluated by calibrated fluorescent 
beads as described previously (18). The fraction of ERK-bound 
MEK (Bound MEK/Total MEK) in individual cells was 















where 0.16 is the maximal FRET efficiency between 
mVenus-MEK1 and mCFP-ERK2, and 0.57 is a quantum yield 
of Venus (19). The dissociation constant value was calculated by 












where Kd is a dissociation constant.  
 
In vitro binding assay. Various concentration of 
GST-ERK2KR and 100 nM 12His-FLAG-MEK1WT were 
incubated with in vitro binding buffer (PBS, 0.1% Tween-20, 1 
mM MgCl2, 40 mM imidazole). Bound protein was pulled 
down by Ni-NTA agarose beads (Qiagen, Valencia, CA), 
washed with in vitro binding buffer three times, and eluted with 
200 mM imidazole-containing PBS. Each eluate was analyzed 
by SDS-PAGE and western blotting. 
 
Surface plasmon resonance assay. Surface plasmon 
resonance spectroscopy was performed with a BIAcore-X 
optical biosensor instrument (Biacore AB, Uppsala, Sweden) 
using a NTA sensor chip (NTA bound to a solid support) as 
described previously (20). Briefly, surface plasmon resonance 
buffers were as follows: (i) regeneration buffer: 10 mM Hepes, 
0.15 M NaCl, 0.35 M EDTA, pH 7.4; (ii) nickel buffer: 500 M 
NiSO4 in running buffer; (iii) running buffer: PBS with 1 mM 
MgCl2, 0.1 % (v/v) Surfactant 20, pH 7.4. Ligand 
(12His-tagged MEK1WT) and analyte (GST-tagged ERK2KR) 
were dissolved in running buffer. All reactions were done at 
25 °C. The data were analyzed using BIAevaluation 3.0 
software (Biacore AB) and kinetic analyses of primary 
sensorgrams were carried out by global fitting using a 
modified-heterogeneous binding model to consider non-specific 
binding of the analyte to Ni-NTA chip sensor. 
 
Nucleocytoplasmic shuttling rates of MEK and ERK. To 
measure nuclear import and export rates, we used a 
rapamycin-induced dimerization system of an FK506-binding 
protein (FKBP12 or FKBP) and FRB domain. For measurement 
of nuclear import rates, Histon H1-fused FRB (H1-FRB) was 
employed as a binder for FKBP-fused proteins. Similarly, the 
nuclear export rate of ERK was determined with an FRB fused 
to the nuclear export sequence (NES). We measured nuclear 
import and export rates of phospho-isoforms of ERK as follows: 
phosphorylation of ERK2T188A or ERK2Y190F was induced 
by the stimulation of EGF and bpV for 10 min. Then, 
Rapamycin was added to the cells in order to trap 
phosphorylated ERK in nucleus or cytoplasm. The fraction of 
phospho-isoforms of ERK was measured by Phos-tag Western 
blotting analysis (Fig. S3A). We utilized this fraction value for 
the exponential curve fitting. Furthermore, the contribution of 
MEK-dependent active nuclear export of ERK was ignored, 
because the nuclear import rate of MEK (4.0 x 10-4 [/sec]) was 
considerably slower than the nuclear import and export rates of 
ERK under the time scale used in our simulation model (~30 
min). From these data, we show that pTpY-ERK seems to be 
actively imported into the nucleus. Unexpectedly, the nuclear 
export rate of pT-ERK is larger than those of the other 
phospho-isoforms. Thus, both the fast import of pTpY-ERK and 
the fast export of pT-ERK contribute to the increase in 
pTpY-ERK accumulation in HeLa cells. 
 
Phosphorylation rates of ERK in vitro. Each experiment 
included a series of diluted GST-ERK concentration as shown in 
Fig. S5. These eluates were subjected into Phos-tag western 
blotting. The amounts of phospho-isoforms of ERK were 
quantified and fitted by global least-square regression algorithm 
to solutions of following differential equations with Microsoft 
Excel Solver: 
     
         













where [MEK], [np-ERK], [pY-ERK], and [pTpYhK] are 
concentration of MEK, np-ERK, pY-ERK, and pTpY-ERK, 
respectively. kf1 and kf2 are phosphorylation rate constants 
[/M/sec], which are enzymatically identical to kcat/Km at 
substrate concentrations significantly lower than Km. Initial 
velocity of the phosphorylation was plotted against the substrate 
concentration (Fig. S5C). The initial velocity was not saturated 
up to 1.5 x 10-6 M, indicating that the Michaelis constant of the 
first phosphorylation step is over this range. Therefore, we 
assumed the linear reaction rates of ERK phosphorylation at 
least in the range of ERK concentrations. 
 
siRNA for scaffold proteins and quantitative RT-PCR. 
Scramble siRNA and validated siRNAs for human KSR1 (#1 
and #2) were purchased from Invitrogen (San Diego, CA). 
siRNAs for human MP1, IQGAP1, Paxillin, -arrestin1, and 
-arrestin2 were obtained Santa Cruz Biotechnology (Santa 
Cruz, CA). HeLa cells were transfected with 20 M control 
siRNA or siRNA for a scaffold protein by Lipofectamine 
RNAiMAX (Invitrogen). Three days after transfection, total 
RNA was purified by RNeasy Mini Kit (QIAGEN, Hilden, 
Germany), and reverse-transcribed by High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, Foster City, 
CA) according to the manufacture’s protocol. Then, expression 
levels of scaffold protein and GAPDH were analyzed by SYBR 
GreenER qPCR SuperMix (Invitrogen) with ABI PRISM7000 
Sequence Detection System (Applied Biosystems). Primers used 
for real time PCR analysis were listed as follows. GAPDH: 
(Fw) 5’-GAGTCCACTGGCGTCTTCAC-3’ and (Rv) 
5’-GTTCACACCCATGACGAACA-3’, KSR1: (Fw) 
5’-TCTCCCACCCTGGACACTT-3’ and (Rv) 
5’-GAGGAAGAAAGCCCCTGGT-3’ MP1: (Fw) 
5’-TGTCAGATAGAGATGGAGTACCTGTT-3’ and (Rv) 
5’-AAACCAGGTCGCAAAGCAT-3’, IQGAP1: (Fw) 
5’-TGTGCAAAATTCTATGCAGCTT-3’ and (Rv) 
5’-GGCAGTCACCCCAGAGATAG-3’, Paxillin: (Fw) 
5’-CAGCAGACACGCATCTCG-3’ and (Rv) 
5’-GAGCTGCTCCCTGTCTTCC-3’,  -arrestin1: (Fw) 
5’-ACTATGAAGTCAAAGCCTTCTGC-3’ and (Rv) 
5’-GGATGACCAGACGCACAGA-3’,  -arrestin2: (Fw) 
5’-GGAAACTCAAGCACGAGGAC-3’ and (Rv) 
5’-CTTGTTGGCACCCTCCTTC-3’ 
 
Kinetic modeling and numerical simulation. All kinetic 
reactions were described with mass action kinetics by using 
CellDesigner (version 4.0 beta) (21) (Fig. 3A, 4A, and S8). 
Then, the ordinary differential equations and parameters were 
exported to the MATLAB software (version R2008b or R2010b; 
The Mathworks Inc., Natick, MA) through Systems Biology 
Workbench (version 2.7.8) (22). Numerical simulation was 
performed by MATLAB software with ode23 function. To 
ensure consistency of simulation results with western blot 
results, concentration of phospho-isoforms of ERK was 
represented by summing all ERK species in nucleus and 
cytoplasm.  
 
3Parameter search and evaluation. Parameter search was 
performed by using fminseach function in MATLAB (Fig. S11). 
The target function for parameter search was residual sum of 
square (RSS) between the experimental data (Fig. 2E and Fig. 
4D) and simulation data in distributive model or processive 
model. The fminsearch function found a parameter set that 
minimized the RSS value to fit simulation data with 
experimental data. After finding optimized parameters in each 
of the distributive and processive models, the RSS value and the 
number of parameters for optimization were utilized to calculate 
Akaike information criterion (AIC) value for ranking which of 
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Fig. S1. Quantification of protein concentrations, dissociation constant, and nucleocytoplasmic shuttling rates. (A and 
B) For the determination of the molecule numbers of MEK and ERK, serial dilution of recombinant GST-tagged proteins 
and total cell lysates of HeLa cells were separated by SDS-PAGE, followed by immunoblotting with anti-MEK1/2 (A) and 
anti-ERK1/2 (B) antibodies. The bound antibodies were detected and quantified. (C and D) The bands in A and B were 
quantified and plotted as scatter plots, showing the linear relation between intensity and dilution of molecules and cell 
number. (E) For quantification of the volume of the cytoplasm and nucleus, HeLa cells were trypsinized and stained with 
Höechst 33258. Cells were imaged with differential interference contrast microscopy (upper, cytoplasm and nucleus) or 
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Fig. S2. Measurements of dissociation constant for the binding of MEK and ERK. (A) HeLa cells were transfected with 
plasmids encoding mVenus-MEK1 and mCFP-ERK2 as indicated ratio. Images of YFP, CFP and FRET were acquired two 
days after transfection. Then, corrected FRET image (cFRET) images were created by several corrections described in SI 
Materials and Methods. cFRET/YFP ratio images are shown in the intensity-modulated display mode, in which eight colors 
from red to blue are used to represent the cFRET/YFP ratio with the intensity of each color indicating the mean intensity of 
cFRET and YFP. The upper and lower limits of the ratio range are shown in the bottom. (B) Fraction of ERK-bound MEK 
(Bound MEK/Total MEK) versus the concentration of free ERK in each cell is plotted with the fitted curve. The dissociation 
constant was calculated as described in SI Materials and Methods. (C) Dissociation constant between MEK and ERK was 
measured by using in vitro binding assay. (D) The amount of bound versus free ERK is plotted with the fitted curve (Kd is 
1.5 x 10-6 M). (E) Interaction between MEK and ERK was monitored in real time by surface plasmon resonance 
spectroscopy analysis. Increasing concentrations of ERK (0.25-4.0 x 10-6 M) were passed over a sensor chip with 
immobilized MEK for 60 s (association phase) before the flow was switched to buffer alone for another 60 s (dissociation 
phase). Association and dissociation rate constants were derived using BIAevaluation 4.1 software. 
Fig. S3 
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Fig. S3. Measurements of nucleocytoplasmic shuttling rates of phospho-isoforms of ERK. (A) HeLa cells expressing 
mVenus/FKBP-tagged ERK wild type (WT), T188A, or Y190F were serum-starved for 6-12 h and stimulated with 2.0 x 10-6 
g/l EGF and 1.0 x 10-4 M bpV for 10 min. Cells were lysed and subjected to Phos-tag western blotting with anti-GFP 
antibody. The four phospho-isoforms of ERK are indicated on the right: np, non-phosphorylated; pT, threonine 
mono-phosphorylated; pY, tyrosine mono-phosphorylated; pTpY, threonine and tyrosine bis-phosphorylated (see Fig. S4 in 
detail). (B and C) HeLa cells expressing the proteins indicated at the bottom were stimulated with 2.0 x 10-6 g/l EGF and 1.0 
x 10-4 M bpV for 10 min, followed by the addition of 2.5 x 10-7 M Rapamycin to trap the proteins at nucleus (B) or 
cytoplasm (C). (D and E) After Rapamycin treatment, the nuclear fluorescence intensity was monitored and fitted with single 
(np-ERK), double (pY-ERK, pT-ERK), or triple (pTpY-ERK) exponential curves. The fraction of each exponential curve was 
determined from the data shown in A. The nuclear import (D) and export (E) rates of each phospho-isoform was obtained 
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Fig. S4. Separation of phospho-isoforms of ERK by phospho-affinity gel electrophoresis. (A) GST-tagged Xenopus 
ERK2-KR (K57R, kinase-dead mutant) was phosphorylated in vitro by His-tagged Xenopus MEK1-SDSE (constitutively 
active mutant) for the indicated periods. Phosphorylated proteins were identified by Phos-tag western blot analysis with 
anti-ERK1/2 (upper and lower), anti-pTpY-ERK1/2 (upper), and anti-pY-ERK1/2 antibodies (lower). Non-phosphorylated 
ERK (np-ERK), tyrosine mono-phosphorylated ERK (pY-ERK), and tyrosine and threonine bis-phosphorylated ERK 
(pTpY-ERK) are denoted on the right. (B) GST-pTpY-ERK2 was dephosphorylated by His-tagged PTP1B to generate 
pT-ERK2. Phosphorylated proteins were analyzed by using anti-ERK1/2 (upper and lower), anti-pTpY-ERK1/2 (upper), and 
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Fig. S5. Measurement of phosphorylation rates in vitro. (A) GST-ERK2-KR at the indicated concentrations was 
phosphorylated by His-tagged MEK1-SDSE (3.0 x 10-7 M) in the presence of 1.0 x 10-3 M ATP for the indicated time period, 
followed by Phos-tag western blot analysis. Non-phosphorylated ERK (np-ERK), tyrosine mono-phosphorylated ERK 
(pY-ERK), and tyrosine and threonine bis-phosphorylated ERK (pTpY-ERK) are denoted on the right. (B) The amounts of 
phospho-isoforms of ERK were quantified by subtracting the amount of non-reactive ERK, and plotted as circles. The data 
were fitted by a global least-square regression algorithm to a two-steps first-order phosphorylation model to obtain kinetic 
parameters. (C) The initial velocity of the first phosphorylation step is plotted against the substrate concentration. The 
velocity is not saturated in up to 1.5 x 10-6 M of substrate, indicating that the Michaelis constant of this phosphorylation step 
is larger than this range. (D) A Lineweaver-Burk plot of the first phosphorylation step is shown with the linear regression 
line. (E) GST-pT-ERK2-KR was phosphorylated by His-tagged MEK1-SDSE in the presence of 1.0 x 10-3 M ATP for the 
indicated period, followed by Phos-tag western blot analysis. (F) The amounts of phospho-isoforms of ERK were quantified 
and plotted. The data were fitted to a one-step first-order phosphorylation model to obtain kinetic parameters. (G) Schematic 




































































































































































































































































































































































































































































































Fig. S6. Measurement of the dephosphorylation rate of ERK. (A) HeLa cells stably expressing NES-ERK2-mVenus 
(upper) or ERK2-mCFP-NLS with NLS-MEK1 (lower) were serum starved for 12 hours. Cells were left untreated or treated 
with 1.0 x 10-5 g/l EGF for 5 minutes, followed by 1.0 x 10-5 M PD184352 with mock (left), 1.0 x 10-7 M Calyculin A 
(center) or 1.0 x 10-4 M bpV (right) for the indicated time periods. Cell lysates were subjected to Phos-tag western blot 
analysis using anti-GFP and anti-pTpY-ERK antibodies. We repeated the same experiments four times with reproducible 
results, and representative results are shown. (B) Scheme of two dephosphorylation pathways for pTpY-ERK. (C) The 
decrease of pTpY-ERK after MEK inhibition by PD184352 in the presence or absence of Calyculin A was monitored in 
cytosol (upper) and nucleus (lower). Bars are SD (n = 4). (E and F) The dephosphorylation rates [/sec] in cytosol (D) and 
nucleus (E) were measured by fitting the time course of pTpY-ERK decay shown in C with an exponential decay function. 
Dephosphorylation rates from pTpY-ERK to pT-ERK were simply interpreted as the decay rates with Calyculin A. 
Dephosphorylation rates from pTpY-ERK to pY-ERK were obtained by subtracting total dephosphorylation rates from those 
of pTpY-ERK to pT-ERK. (F) Scheme of dephosphorylation pathways for pY-ERK. Calyculin A prevents an influx of 
pY-ERK via pTpY-ERK. (G) The decrease of pY-ERK upon MEK inhibition by PD184352 in the presence of Calyculin A 
was monitored in cytosol (left) and nucleus (right). Bars are SD (n = 4). (H) The dephosphorylation rates [/sec] in cytosol 
and nucleus were measured by fitting the time course of pY-ERK decay with an exponential function. (I) Scheme of 
dephosphorylation pathways for pT-ERK. bpV prevents an influx of pT-ERK via pTpY-ERK. (J) The decrease of pT-ERK 
upon MEK inhibition by PD184352 in the presence of bpV was monitored in cytosol (left) and nucleus (right). Bars are SD 
(n = 4). (K) The dephosphorylation rates [/sec] in cytosol and nucleus were measured by fitting the time course of pT-ERK 
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Fig. S7. Measurement of the dephosphorylation rate of MEK. To measure the MEK dephosphorylation rate in HeLa cells, 
we generated a HeLa cell line stably expressing cRaf-FKBP and LDR. Upon Rapamycin treatment of this cell line, 
cRaf-FKBP is recruited to plasma membrane and activated rapidly. Consequently, MEK is phosphorylated by the 
cRaf-FKBP without any perturbations of other signaling pathways. (A) The HeLa cells were left untreated or pretreated with 
a cRaf inhibitor, ZM336372, for 10 min, and then stimulated with Rapamycin for 30 min. The cell lysates were subjected to 
SDS PAGE and analyzed by anti-phospho-MEK1/2 (upper) and anti-MEK1/2 (lower) antibodies. (B and C) Measurement of 
the dephosphorylation rate of MEK. (B) The aforementioned HeLa cells were treated with or without Rapamycin for 15 min, 
and then treated with ZM336372 for the indicated time period. The cell lysates were collected and subjected to SDS-PAGE 
followed by immunoblotting analysis with anti-phospho-MEK1/2 (upper) and anti-MEK1/2 (lower) antibodies. These 
experiments were repeated three times and representative results are shown. (C) The relative amount of phosphorylated 
MEK1/2 was measured and plotted as a function of time after ZM336372 addition (min). The decay of MEK is fitted to the 





















































































Fig. S8. Diagram of the distributive and processive model. (A) A process diagram of the distributive phosphorylation 
model of the MEK-ERK module was represented. The arrows represent the reactions (Re), which are numbered from 1 to 17 
as described in the Table S2. (B) A process diagram of the processive phosphorylation model of the MEK-ERK module. The 
arrows represent the reactions (Re), which are numbered from 1 to 20 as described in the Table S2. Blue numbers are 

















































































































































































































































































































































































Fig. S9. Dynamics of ERK phosphorylation with varying MEK activity. Experimentally-determined parameters were 
used for the numerical simulations based on the distributive model and processive model. (A) Heat maps of the 
concentration of phosphorylated MEK upon stimulation in distributive model (left) and processive model (right). Horizontal 
and vertical axes indicate time after stimulation (minute) and kcat/Km value (Raf_kphos) of cRaf kinase for MEK 
phosphorylation as an input strength, respectively. (B) HeLa cells were stimulated with 1.0 x 10-5 g/l EGF, and lysed with 
SDS sample buffer at the indicated time points. The cell lysates were subjected to Western blotting analysis with 
anti-MEK1/2 and anti-phospho-MEK1/2 antibodies. The ratio of phospho-MEK to MEK (pMEK/MEK) is plotted against 
the time after EGF stimulation (red circle). In addition, the time course of MEK phosphorylation in the distributive model at 
kcat/Km value of 1.0 x 106 [/M/sec] is superimposed in the same figure. (C and D) Shown here are the heat maps of the 












































































































































































































































































Fig. S10. Dynamics of ERK phosphorylation in the absence of dephosphorylation pathways. Shown here are heat maps 
of concentration of the indicated phospho-isoforms of ERK upon stimulation in the distributive model (A) and processive 
model (D) as well as shown in Figure S9 except for the lack of dephosphorylation pathways. 
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Condition 1 Condition 2 Condition 3
RSS AIC nH Variables RSS AIC nH Variables
Condition 1 1.165 -36.3 1.66 1 0.421 -51.6 1.12 1
Condition 2 0.382 -49.0 1.79 3 0.275 -52.0 1.13 4
Condition 3 0.204 -42.5 2.27 11 0.180 -42.3 1.42 12
Processive modelDistributive model
 
Fig. S11. Numerical validation of the processive phosphorylation model. (A) Numerical validation of the 
phosphorylation models by parameter fittings. (A) The conditions for the parameter fittings are illustrated. Black lines 
represent reactions to be optimized by parameter search. Condition 1 (left) aims to fit the data (Fig. 2E and Fig. 4D) by 
optimizing the quantity of the activated MEK; therefore the models have only 1 degree of freedom. Condition 2 (middle) 
aims to fit the data by independently changing the MEK activities against np-ERK, pY-ERK, and pT-ERK, allowing 3 and 4 
degrees of freedom in the distributive and processive models, respectively. Condition 3 (right) aims to fit the data by 
changing all phosphorylation and dephosphorylation rates, allowing 11 and 12 degrees of freedom in the distributive and 
processive models, respectively. (B) The results of curve fitting are shown with the experimental data in Fig. 2E and Fig. 4D. 
(C) A table presents a summary of the parameter fitting. RSS, AIC, and nH refer to residual sum of square, Akaike 
information criterion, and Hill coefficient, respectively. Based on the AIC and Hill coefficient values, the processive model 
in Condition 2 is the most plausible model. In Condition 3, even though the AIC value of the distributive model is 
comparable to that of the processive model, the AIC value is much larger than that obtained for the processive model in 





































Phos-tag western blotting  
Fig. S12. In vitro ERK phosphorylation by using cell extract. Cytoplasmic extract prepared from HEK-293F cells were 
diluted with in vitro kinase buffer containing ATP and constitutively active MEK, and incubated for the indicated period 
(min). (A) The reaction solution were subjected to Phos-tag western blotting analysis. (B) The fractions of np-ERK2 (blue), 














Fig. S13. Processive phosphorylation of p38 
MAP kinase. (A) HeLa cells were stimulated 
with 1.0 x 10-3 g/l anisomycin at the indicated 
time. Cell lysates were subjected to Phos-tag 
western blot analysis. (B) HeLa cells were 
stimulated with indicated concentration of 
anisomycin for 30 min. Cell lysates were 
subjected to Phos-tag western blot analysis. (C 
and D) The phospho-isoforms of p38 in A and 
B were quantified and plotted. Notably, 
preceding accumulation of pY-p38, which was 
typical hallmark of distributive phosphorylation, 
was not observed in time-course (C) and 
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Fig. S14. Effects of scaffold proteins on the mode of ERK phosphorylation. (A) HeLa cells were transfected with siRNA 
for control or scaffold proteins as indicated. Three days after transfection, the HeLa cells were stimulated with 1.0 x 10-5 g/l 
EGF and analyzed at the indicated time. Cells were subjected to Phos-tag western blot analysis. Knockdown efficiency 
(KD, %) of siRNA was determined by quantitative RT-PCR analysis. (B) The phospho-isoforms of ERK quantified in A are 






Table S1. Concentration of cRaf, MEK, and ERK in a HeLa cell. 
 
Average SD N
cRaf 1.3 x 10-8 - - Fujioka et al. JBC 2006
MEK 1.2 x 10-6 5.2 x 10-7 3 Fig. S1





Cytoplasm 2.8 x 10-12 7.6 x 10-13 20 Fig. S1












Table S2. Kinetic models and parameters. 
Average SD Unit N
kf 1.0 x 106 - /M/sec - Arbitrary
kb 9.6 x 10-3 2.2 x 10-3 /sec 3 Fig. S7
kf 1.8 x 105 - /M/sec 1
kb 2.7 x 10-1 - /sec 1
kf 1.7 x 10-3 5.5 x 10-4 /sec 17 Fig. S3
kb 1.3 x 10-2 3.5 x 10-3 /sec 7 Fig. S3
kf 2.5 x 10-3 7.9 x 10-4 /sec 19 Fig. S3
kb 1.7 x 10-2 4.6 x 10-3 /sec 10 Fig. S3
kf 2.2 x 10-3 9.9 x 10-4 /sec 16 Fig. S3
kb 4.9 x 10-2 2.0 x 10-2 /sec 7 Fig. S3
kf 8.2 x 10-3 5.7 x 10-3 /sec 15 Fig. S3
kb 7.6 x 10-3 3.6 x 10-3 /sec 16 Fig. S3
kf 1.8 x 105 - /M/sec -



























kf 5.0 x 10-2 /sec Estimated from Figure 2E
Re18






kf 7.3 x 10-2 /sec Calculated from Re15 and Re 184
Re17
pT-ERK_cyt + pMEK ->
pTpY-ERK_cyt
kf 2.0 x 104 /M/sec Fig. S5-
Re16
pY-ERK_cyt + pMEK ->
pTpY-ERK_cyt
kf 2.1 x 104 /M/sec Fig. S521.1 x 104
Re15
np-ERK_cyt + pMEK ->
pY-ERK_cyt













































MEK + cRaf <=>
pMEK
Re2






The reaction number is indicated in Figure S8A and S8B. Bold character means enzyme. The symbols <=> and -> indicate a 
reversible reaction and an irreversible reaction, respectively. kf and kb are forward and reverse kinetic parameters, 
respectively. 
 
1 kf and kb are obtained by Biacore with 5 different sets of ligand concentration. Dissociation constants, which are measured 
by FRET and in vitro binding assay, are 1.7 x 10^-6 ± 6.8 x 10 ^-7 [M] (N = 3) (Fig. S2A and B) and 1.8 x 10^-6 [M] (N = 
1) (Fig. S2C and D), respectively. 
2 Parameters are obtained by global fitting of 2 independent experiments with 10 different sets of substrate and enzyme 
concentration. 
3 Assuming that the association/dissociation rate constants of the binding bewtween pMEK and ERK are comparable with 
them of the binding of MEK and ERK. 




Table S3. Summary of parameters fitted with three different conditions in Figure S11. 
 
The reaction number is indicated in Figure S8A and S8B. Bold character means enzyme. The symbols <=> and -> indicate a 
















































kf 2.1 x 104 /M/sec













kf 2.0 x 104
























- 3.0 x 10-4
- 1.2 x 10-3
1.0 x 10-3
2.8 x 10-3
- 2.3 x 10-3
4.2 x 10-2
Initial value (Unit)
7.8 x 10-3
6.9 x 10-3
2.0 x 104
3.3 x 104
3.2 x 10-2
4.6 x 104
2.3 x 104
